ArticleInternational ophthalmology2026
Improvement in visual outcomes in diabetic macular edema through the reduction of macular thickness fluctuations using the 0, 19 mg fluocinolone acetonide implant.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to assess the effectiveness of 0.19-mg fluocinolone acetonide intravitreal (FAc) implant to control retinal thickness fluctuations (RTF) in diabetic macular edema (DME) and its effect on best-corrected visual acuity (BCVA).
methodsThe RIVER study was a multicenter, retrospective, non-interventional study analyzing data of the Retina.pt portuguese national registry in DME. Retinal thickness was assessed using the spectral domain optical coherence tomography (SD-OCT). The primary endpoint was the assessment of RTF along the follow-up, through the combined measurement of retinal thickness amplitude (RTA), retinal thickness standard deviation (RTSD), and central subfield thickness area under the curve (CST-AUC). Eyes were stratified into quartiles (Q) and median-split according to these variables.
resultsThe mean follow-up time after the FAc implantation was 82 ± 26, 96 months. From baseline to last follow-up visit after the implant, mean RTA decreased from 187.6±150.4 to 151.6±126.4 µm (p=0.1204), mean RTSD significantly reduced from 96.3±78.1 to 60.8±57.3 µm (p=0.0032) and mean CST-AUC significantly reduced from 446 to 349 µm (p<0.0001). BCVA significantly improved in eyes with RTA Q1, Q2, Q3 (p<0.05); eyes with RTSD Q1, Q2, and Q3 (p<0.05); and eyes with CST-AUC Q1, Q2, and Q3 (p<0.05). According to the median split, eyes with RTA and RTSD < to median showed greater BCVA improvement.
conclusionsRetinal thickness fluctuation was significantly reduced after the Fc implant. Moreover, a lower retinal thickness variability tended to be associated with better visual outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.